Bevacizumab

• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
• Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm… Recruiting
  2024-517200-10-00 Phase II 1 country Fondazione Ricerca Traslazionale
• A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatoce… Recruiting
  2023-507689-26-00 Phase III 5 countries Astrazeneca AB
• Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab Recruiting
  2024-517119-59-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• Glioblastoma treatment with irradiation and olaptesed pegol (NOX-A12) in unmethylated patients Recruiting
  2024-510964-21-00 Phase I/II 1 country TME Pharma AG
• DRUP trial Recruiting
  2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial Recruiting
  2024-515626-92-00 Phase II 7 countries Medical University Of Vienna
• Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 W… Ended
  2023-505110-14-00 Phase II 3 countries AbbVie Deutschland GmbH & Co. KG
• Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoe… Ended
  2024-517782-16-00 Phase II 1 country Grupo Espanol Multidisciplinar En Cancer Digestivo
• A PHASE 1/2 STUDY EXPLORING THE SAFETY AND ACTIVITY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH CAPECITABINE AND BEVACIZUMAB IN METASTATIC… Ended
  2024-513271-41-00 Phase II 1 country Fondazione GONO G.I.
• Locally Advanced or Metastatic Hepatocellular Carcinoma: Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination with Budiga… Ended
  2023-504600-28-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
• A trial to find out how safe REGN7075 is and how well it works in combination with cemiplimab for participants with advanced cancers Ended
  2022-501234-37-00 Phase I (FiH) 4 countries Regeneron Pharmaceuticals Inc.
• A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He… Ended
  2023-503422-39-00 Phase III 6 countries F. Hoffmann-La Roche AG
• Master Protocol of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobilia… Ended
  2022-502317-29-00 Phase II 2 countries AstraZeneca AB
• A CLINICAL TRIAL TO CONFIRM THE EFFICACY OF OLAPARIB IN COMBINATION WITH BEVACIZUMAB, ADMINISTERED AS MAINTENANCE THERAPY AFTER A FRONTLINE … Ended
  2022-502242-27-00 Phase IV 1 country Mario Negri Institute For Pharmacological Research
• IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended
  2022-502103-30-00 Phase II 1 country Intergroupe Francophone de Cancerologie Thoracique
• ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w… Ended
  2024-512288-29-00 Phase II 4 countries ETOP IBCSG Partners Foundation
• Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) pati… Ended
  2024-511439-84-00 Phase II 2 countries Klinikum der Universitaet Muenchen AöR
• PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended
  2022-501217-31-00 Phase II/III 1 country Fondation Franc.Cancerologie Digestive
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended
  2023-506241-30-00 Phase III 15 countries Mirati Therapeutics Inc.
• Pembrolizumab/placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer. Ended
  2023-506177-35-00 Phase III/IV 10 countries Merck Sharp & Dohme LLC
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended
  2023-508194-89-00 Phase II 5 countries F. Hoffmann-La Roche AG
• Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab… Ended
  2024-512684-31-00 Phase II 1 country Universitaetsklinikum Regensburg AöR
• MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar… Ended
  2024-516632-99-00 Phase II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Showing 97–120 of 161 trials